Authors:
Launonen, V
Mannermaa, A
Stenback, F
Kosma, VM
Puistola, U
Huusko, P
Anttila, M
Bloigu, R
Saarikoski, S
Kauppila, A
Winqvist, R
Citation: V. Launonen et al., Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables, CANC GENET, 122(1), 2000, pp. 49-54
Authors:
Westerlund, A
Apaja-Sarkkinen, M
Hoyhtya, M
Puistola, U
Turpeenniemi-Hujanen, T
Citation: A. Westerlund et al., Gelatinase A-immunoreactive protein in ovarian lesions - Prognostic value in epithelial ovarian cancer, GYNECOL ONC, 75(1), 1999, pp. 91-98
Authors:
Talvensaari-Mattila, A
Apaja-Sarkkinen, M
Hoyhtya, M
Westerlund, A
Puistola, U
Turpeenniemi-Hujanen, T
Citation: A. Talvensaari-mattila et al., Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation, GYNECOL ONC, 72(3), 1999, pp. 306-311
Authors:
Trope, C
Hogberg, T
Kaern, J
Bertelsen, K
Bjorkholm, E
Boman, K
Himmelmann, A
Horvath, G
Jacobsen, A
Kuoppola, T
Vartianen, J
Lund, B
Onsrud, M
Puistola, U
Salmi, T
Scheistroen, M
Sandvei, R
Simonsen, E
Sorbe, B
Tholander, B
Westberg, R
Citation: C. Trope et al., Long-term results from a phase II study of single agent paclitaxel (Taxol (R)) in previously platinum treated patients with advanced ovarian cancer: The Nordic experience, ANN ONCOL, 9(12), 1998, pp. 1301-1307
Authors:
Launonen, V
Stenback, F
Puistola, U
Bloigu, R
Huusko, P
Kytola, S
Kauppila, A
Winqvist, R
Citation: V. Launonen et al., Chromosome 11q22.3-q25 LOH in ovarian cancer: Association with a more aggressive disease course and involved subregions, GYNECOL ONC, 71(2), 1998, pp. 299-304
Authors:
Santala, M
Risteli, J
Risteli, L
Puistola, U
Kacinski, BM
Stanley, ER
Kauppila, A
Citation: M. Santala et al., Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer, BR J CANC, 77(11), 1998, pp. 1825-1831